Abeona Therapeutics, Inc. (ABEO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Abeona Therapeutics, Inc. (ABEO)
Go deeper and ask any question about ABEO
Company Performance
Current Price
as of Sep 13, 2024$5.58
P/E Ratio
N/A
Market Cap
$241.69M
Description
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Metrics
Overview
- HQCleveland, OH
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerABEO
- Price$5.580.00%
Trading Information
- Market Cap$241.69M
- Float90.42%
- Average Daily Volume (1m)204,018
- Average Daily Volume (3m)332,489
- EPS-$2.10
Company
- RevenueN/A
- Rev Growth (1yr)-100.00%
- Net Income$7.41M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$16.20M
- EV$117.32M
- EV/RevenueN/A
- P/EN/A
- P/SN/A